N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester:Exports & Compliance White Paper 2026

I. Executive Summary

N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-alanine 2-ethylbutyl ester (CAS 1354823-36-1) is a phosphoramidate ProTide-type side chain supplied as a registered starting material or advanced intermediate for the synthesis of nucleotide prodrug antiviral APIs. It carries a stereogenic phosphorus centre, an L-alanine linker, a 2-ethylbutyl ester and an aryl leaving group, and is delivered into GMP or research-use-only campaigns under custom-synthesis agreements. This article treats it strictly as an industrial intermediate; no therapeutic claim is made or implied.

Two features dominate procurement. The first is P-stereochemistry: the Sp and Rp diastereomers behave differently in downstream processing, so the specification fixes the diastereomeric ratio by chiral HPLC or supercritical fluid chromatography and controls drift during coupling, isolation and storage. The second is the leaving group. This nitro-substituted phenoxy variant, unlike the pentafluorophenoxy analogue of the same ProTide family, contains no perfluoroaromatic moiety, removing it from per- and polyfluoroalkyl scrutiny but introducing nitrophenol limits.

This paper covers ProTide chemistry at route-class level, the critical quality attributes that decide qualification, the GMP and DMF perimeter, containment and know-your-customer obligations, and the Chinese, Indian and Western CDMO ecosystems that expanded during the pandemic and are now normalising.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule is a phosphoramidate triester: a pentavalent phosphorus bearing a phenoxy group, a 4-nitrophenoxy leaving group, the nitrogen of L-alanine and, through the alanine carboxyl, a 2-ethylbutyl ester. It is typically an oil or low-melting amorphous solid, sensitive to moisture and heat and prone to hydrolysis at the P–N and P–O bonds. The compound has no approved therapeutic indication of its own; it is a chemical intermediate.

• Phosphorus Stereochemistry and Diastereomeric Control: The phosphorus is a stereocentre, so the substance exists as Sp and Rp diastereomers that are separable by chromatography and interconvert only through bond cleavage. Because the customer's coupling step transfers that configuration into the API, the diastereomeric ratio is a critical quality attribute, and any process step that cleaves and reforms the P–N bond is a potential source of drift.
• Leaving-Group Electronics and Impurity Consequences: Electron-withdrawing substituents on the aryloxy group tune the reactivity of the phosphorus toward the nucleoside coupling partner and determine which phenolic residues appear in the impurity profile. A nitro-substituted phenoxy group delivers comparable activation to fluorinated analogues but generates nitrophenol rather than a perfluorinated phenol as the residual, which changes the questions buyers ask.

2.2 Synthesis and Manufacturing Technologies

Industrial preparation belongs to the phosphoramidate-coupling route class. An aryl phosphorodichloridate or an equivalently activated phosphorylating agent is combined with an L-alanine 2-ethylbutyl ester salt at low temperature under a carefully chosen base, and the resulting diastereomeric mixture is then resolved. Because both reagent and product are moisture-sensitive, the campaign is run dry, cold and under nitrogen, with tight control of stoichiometry, addition rate and work-up pH.

• Coupling Selectivity and Hydrolysis Suppression: The competitive reaction is hydrolysis: water attacks the activated phosphorus to give the phosphate and free phenol, lowering yield and creating the impurity species that later dominate the specification. Producers control it through reagent drying, temperature, base selection and addition rate, then quench cold. Where the customer requires a specific diastereomer, the coupling is designed to bias the ratio before purification rather than relying on resolution alone.
• Chiral Preparative SFC, HPLC and Crystallisation: Commercial-scale resolution is usually chromatographic: preparative supercritical fluid chromatography or chiral HPLC separates the diastereomers with high productivity and avoids the solvent load of classical crystallisation. Diastereomeric salt or solvate crystallisation remains attractive where a suitable solid form exists, because it is cheaper and scales more simply, and hybrid sequences that enrich by crystallisation then polish chromatographically are increasingly common.

2.3 Core Application Matrix

• Nucleotide Prodrug API Intermediate: The principal outlet: the fragment is coupled to a nucleoside in the customer's GMP process and carried through to the prodrug API. Supply is therefore governed by the customer's filing and by a DMF or ASMF that documents the route, the impurity rationale and the specification.
• Process Development and Analytical Reference Material: Research-use-only grade is purchased for route scouting, method development and specification setting, including isolated diastereomer and phenolic residue standards. These buyers value speed, small lot sizes and a certificate of analysis that reports the actual diastereomeric ratio rather than a pass statement.
• ProTide Analogue and Library Synthesis: Discovery programmes commission custom synthesis of ProTide variants — alternative leaving groups, ester motifs and amino-acid linkers — to explore structure–property relationships. This work is quoted as a service rather than as a product, under confidentiality, and is supplied research use only.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand for this intermediate has moved through a sharp pandemic-driven expansion followed by normalisation. Emergency-scale programmes pulled forward years of capacity investment, qualified multiple suppliers in parallel; as those programmes settled, demand reverted to a smaller, steadier base supported by antiviral pipeline work, generic and voluntary-licence production, and ProTide research. Buyers who qualified on speed during the emergency are now requalifying on documentation, diastereomeric control and cost.

3.2 Capacity Distribution and Export Flows

Capacity follows the nucleotide and CDMO map. Chinese producers in Jiangsu, Zhejiang, Shandong and Sichuan built phosphoramidate and nucleoside capacity rapidly and now export both intermediate and API-grade material, often with integrated chromatography. Indian suppliers in the Hyderabad, Bengaluru and Vizag corridor hold strong positions through voluntary-licence and generic supply chains. European and North American CDMOs retain the high-documentation end, with containment capability, DMF experience and proximity to innovator filings, and frequently act as second-source qualifiers.

3.3 Market Bifurcation and Pricing Dynamics

Pricing is driven less by raw materials than by resolution cost and documentation. Chromatographic purification sets a hard floor, because solvent and stationary-phase consumption scale with the diastereomeric excess demanded, so a tighter specification translates directly into higher unit cost. GMP material made under ICH Q7 with DMF support, validated chiral methods and full ICH Q3C, Q3D and M7 packages commands a large premium over research-use-only material of nominally similar purity, and that premium has widened as purchasing moved back to documentation.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

An intermediate is not approved in isolation: it is reviewed as part of the applicant's dossier, and the supplier's obligations are chemical inventory law, GMP conformity and documentation support. For this molecule those obligations are unusually demanding because the campaign sits inside an antiviral supply chain, which attracts end-use scrutiny, export-control awareness and know-your-customer expectations well beyond those of a typical fine chemical.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH, CLP and Nitrophenol Classification: As a defined monosubstance it requires a REACH registration, or coverage through an only representative appointed by a non-EU manufacturer, above one tonne per year; research-and-development and strictly-controlled-condition routes may reduce but do not remove the obligation. CLP classification, an Annex II SDS and, for mixtures, a UFI-bearing poison-centre notification follow. Classification and labelling work must address the nitrophenol moiety specifically, because phenolic residues drive both hazard communication and customer impurity limits.
• PFAS-Adjacency and the Nitro-versus-Perfluoro Contrast: Buyer questionnaires increasingly screen for per- and polyfluoroalkyl substances. Under the OECD definition, PFAS covers substances containing a fully fluorinated methyl or methylene carbon; a nitro-substituted phenoxy group contains no such moiety, so this intermediate is not a PFAS even though it is adjacent to fluorinated ProTide analogues in the same family. Suppliers should answer the questionnaire explicitly rather than remain silent, because the visible structural similarity to pentafluorophenoxy analogues triggers automated flags, and substitution away from perfluoroaromatic leaving groups is now buyer-driven.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Inventory Position and Import Certification: US supply requires the substance to be listed on the TSCA Inventory or covered by a documented exemption — a pre-manufacture notice for a new identity, a low-volume or low-release exemption, or a research-and-development exemption for investigational use. Because pandemic-era ProTide intermediates reached the market quickly, suppliers should re-verify the listing basis for the exact CAS identity before first shipment.
• FDA DMF, ICH Q7 and the RUO Boundary: The FDA reviews the intermediate through the applicant's application, normally via a Type II drug master file referenced by letter of access, and manufacture follows ICH Q7 with ICH Q11 development documentation. Material supplied outside a filing must be labelled research use only and not for human or veterinary use, with no therapeutic or clinical claim. Because the material is an antiviral API precursor, exporters should apply know-your-customer screening and end-use declarations before shipment.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Chromatographic resolution and low-temperature operation make this an energy- and solvent-intensive intermediate, and customers now evaluate that burden as part of supplier qualification. The sustainability conversation is also shaped by leaving-group choice: nitro-substituted phenoxy chemistry avoids perfluoroaromatic residues, which aligns with buyer movement away from fluorinated analogues.

5.1 Carbon Footprint and Circular Economy

The footprint is dominated by preparative chromatography, where solvent consumption and solvent recovery dominate, and by the refrigeration and inert-gas demand of cold, dry processing. Practical reductions come from solvent-recovery loops, from enriching the diastereomeric ratio before chromatography so that less material is processed, from supercritical fluid chromatography that substitutes carbon dioxide for bulk organic solvent, and from heat integration. European customers increasingly request ISO 14067-consistent campaign footprints and Scope 1 and 2 reporting.

5.2 Sustainable Sourcing and Traceability

Traceability obligations are documentary: customers require the route class, solvent list, metal and reagent inventory, and declarations on residual solvents, elemental impurities, nitrosamine precursors and fluorinated-substance status. Where the buyer operates under a voluntary licence or a public-health procurement framework, additional expectations around allocation transparency and end-use declaration apply. ISO 9001 and ISO 14001 certification, EcoVadis or Sedex assessment, and documented occupational-exposure controls complete the qualification file.

VI. Supply Chain Resilience and Export Logistics

Few intermediates punish logistics failures as quickly as this one. Moisture ingress hydrolyses the phosphoramidate, warmth accelerates both hydrolysis and diastereomeric drift, and oxygen and light can degrade the phenolic portion. Campaign planning therefore treats cold, dry, inert and dark as specifications, not as preferences.

6.1 Packaging Standards and Moisture/Contamination Control

• Cold, Dry and Inert Packaging: Fill under nitrogen into dry, sealed containers — amber glass or lined stainless for small lots, sealed drums for larger ones — with desiccant and headspace protection, then ship with temperature logging. Where stability data support it, ship frozen or at 2–8 °C rather than ambient.
• Containment and Occupational Exposure: Handle under an occupational exposure band derived from a health-based exposure limit, with closed charging, local exhaust, isolator or glovebox containment for powder-handling steps, and cleaning verification between campaigns. Documented operator training, spill procedure and exposure monitoring are routinely inspected during customer audits of high-potency and API-adjacent intermediates.

6.2 Dangerous Goods Identification and Transit Protocols

Consignments are frequently not assigned a dangerous-goods class on the basis of available classification data, but the position must be verified per lot rather than assumed, with IMDG, ADR/RID and IATA DGR applied where a solvent-wet or classified form is shipped. Air freight with dry ice adds carbon dioxide as a Class 9 hazard and per-package quantity limits, so refrigerated sea freight with continuous logging is often more robust for bulk. Every shipment should carry a lot-specific certificate of analysis reporting the diastereomeric ratio, residual phenol levels and water, together with the temperature record and, for GMP campaigns, a certificate of compliance.

VII. Enterprise Global Expansion Strategy Guide

Suppliers compete on evidence of control. The sequence below reflects how antiviral and CDMO buyers qualify a ProTide intermediate supplier.

1. Master the Diastereomer and Impurity Story: Validate a chiral HPLC or SFC method that resolves the Sp and Rp diastereomers, report the measured ratio on every certificate of analysis, and identify and limit the phenolic hydrolysis products and any genotoxic alkylating residues under ICH M7 reasoning. Add ICH Q1A stability evidence covering the proposed shipping condition.
2. Build the GMP and Regulatory File: Operate GMP campaigns to ICH Q7 with ICH Q11 development documentation, prepare a Type II drug master file or ASMF with open and restricted parts, complete the ICH Q3C and Q3D assessments, and hold REACH and TSCA positions for the exact CAS identity. Pair the file with ISO 9001 and ISO 14001 certification and change control that notifies customers of route or specification changes in advance.
3. Protect the Boundary and Offer Capacity: Run know-your-customer and end-use screening on every enquiry, respect IP and licensing boundaries in tech transfer, and decline work that cannot be documented. Commercially, offer both GMP and research-use-only campaigns, invest in preparative chromatography capacity with solvent recovery, and sell reliability of cold-chain delivery as a differentiator.

VIII. Conclusion

N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-alanine 2-ethylbutyl ester is a technically demanding intermediate whose commercial value rests on two controllable variables: phosphorus stereochemistry and hydrolytic stability. Pandemic-era demand accelerated capacity building across China and India and compressed qualification timelines, but the market has since normalised onto a smaller base where documentation, diastereomeric control and delivery reliability decide awards rather than availability alone.

Suppliers who treat the diastereomeric ratio, phenolic residues, ICH M7 alkylating impurities and cold-chain integrity as release-critical will be first qualified when the next ProTide programme appears. Those who compete on nominal purity and price will be limited to research-use-only orders, and will find that the absence of a validated chiral method or of a documented fluorinated-substance position ends the conversation before commercial terms are discussed.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-alanine 2-ethylbutyl ester Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-alanine 2-ethylbutyl ester supply chain:

• China (Jiangsu, Zhejiang and Sichuan): The fastest-scaling phosphoramidate base, built out during pandemic demand, combining phosphorylating-agent production, nucleoside chemistry and preparative chromatography in one corridor. These suppliers compete on scale, speed and integrated purification, and increasingly hold ICH Q7-aligned systems and DMF-support experience for export into regulated markets.
• India (Hyderabad, Bengaluru and Vizag): A nucleotide and CDMO corridor integrated with voluntary-licence and generic supply chains, with established experience in phosphorylated intermediates, ICH-compliant documentation and US and EU filings. Indian suppliers typically win on regulatory maturity, cost position at multi-kilogram scale and willingness to run long-term campaigns.
• Europe and North America: Western CDMOs hold the high-documentation end, offering containment capability under occupational exposure bands, validated chiral separations, DMF and ASMF support and proximity to innovator filings. They are frequently qualified as second sources and set the documentation standard that Asian exporters are measured against.